Home » Scynexis cGMP Facilities Audited by FDA — No Form 483 Observations Issued
Scynexis cGMP Facilities Audited by FDA — No Form 483 Observations Issued
SCYNEXIS, Inc., a fully-integrated drug discovery and development company, announced that the U.S. Food and Drug Administration (FDA) completed its cGMP
compliance inspection of the SCYNEXIS Process Chemistry, Analytical and Manufacturing facilities.
GEN
GEN
Upcoming Events
-
07May
-
14May
-
30May